Advances in Localized Surface Plasmon Resonance Spectroscopy Biosensing

Abstract

In recent years, localized surface plasmon resonance (LSPR) spectroscopy advancements have made it a sensitive, flexible tool for probing biological interactions. Here, we describe the basic principles of this nanoparticle-based sensing technique, the ways nanoparticles can be tailored to optimize sensing, and examples of novel LSPR spectroscopy applications. These include detecting small molecules via protein conformational changes and resonance LSPR spectroscopy, as well as coupling LSPR with mass spectrometry to identify bound analytes. The last few sections highlight the advantages of single nanoparticle LSPR, in that it lowers limits of detection, allows multiplexing on the nanometer scale, and enables free diffusion of sensors in solution. The cases discussed herein illustrate creative ways that LSPR spectroscopy has been improved to achieve new sensing capabilities.

Keywords::

• biosensing
• imaging
• LSPR
• multiplex
• nanoparticle
• tracking

Financial & competing interests disclosure

The authors gratefully acknowledge support from the National Science Foundation (Grants EEC-0647560, CHE-0911145, DMR-0520513, and BES-0507036), the NIH (4 R56 Grant 5R56DK078691–02), the Defense Advanced Research Projects Agency (Grant FA9550–08–1–0221/P00003) and the National Cancer Institute (1 U54 CA119341–01). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The authors gratefully acknowledge support from the National Science Foundation (Grants EEC-0647560, CHE-0911145, DMR-0520513, and BES-0507036), the NIH (4 R56 Grant 5R56DK078691–02), the Defense Advanced Research Projects Agency (Grant FA9550–08–1–0221/P00003) and the National Cancer Institute (1 U54 CA119341–01). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.